These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22271949)

  • 1. Advance market commitment for pneumococcal vaccines: putting theory into practice.
    Cernuschi T; Furrer E; Schwalbe N; Jones A; Berndt ER; McAdams S
    Bull World Health Organ; 2011 Dec; 89(12):913-8. PubMed ID: 22271949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the pneumococcal vaccine Advance Market Commitment motivating innovation and increasing manufacturing capacity? Some preliminary answers.
    Plahte J
    Vaccine; 2012 Mar; 30(14):2462-6. PubMed ID: 22300720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of insurance status and vaccine cost on physicians' administration of pneumococcal conjugate vaccine.
    Davis MM; Ndiaye SM; Freed GL; Kim CS; Clark SJ
    Pediatrics; 2003 Sep; 112(3 Pt 1):521-6. PubMed ID: 12949277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PneumoADIP: an example of translational research to accelerate pneumococcal vaccination in developing countries.
    Levine OS; Cherian T; Shah R; Batson A
    J Health Popul Nutr; 2004 Sep; 22(3):268-74. PubMed ID: 15609779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic perspectives on the advance market commitment for pneumococcal vaccines.
    Snyder CM; Begor W; Berndt ER
    Health Aff (Millwood); 2011 Aug; 30(8):1508-17. PubMed ID: 21821567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Making new vaccines affordable: a comparison of financing processes used to develop and deploy new meningococcal and pneumococcal conjugate vaccines.
    Hargreaves JR; Greenwood B; Clift C; Goel A; Roemer-Mahler A; Smith R; Heymann DL
    Lancet; 2011 Nov; 378(9806):1885-93. PubMed ID: 21664678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physician perspectives regarding pneumococcal conjugate vaccine.
    Schaffer SJ; Szilagyi PG; Shone LP; Ambrose SJ; Dunn MK; Barth RD; Edwards K; Weinberg GA; Balter S; Schwartz B
    Pediatrics; 2002 Dec; 110(6):e68. PubMed ID: 12456935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of pneumococcal conjugate vaccination in The Gambia.
    Kim SY; Lee G; Goldie SJ
    BMC Infect Dis; 2010 Sep; 10():260. PubMed ID: 20815900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to commentaries.
    Light DW
    Hum Vaccin; 2011 May; 7(5):496. PubMed ID: 21552005
    [No Abstract]   [Full Text] [Related]  

  • 10. Physicians' early challenges related to the pneumococcal conjugate vaccine.
    Davis MM; Andreae M; Freed GL
    Ambul Pediatr; 2001; 1(6):302-5. PubMed ID: 11888419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful introduction of an underutilized elderly pneumococcal vaccine in a national immunization program by integrating the pre-existing public health infrastructure.
    Yang TU; Kim E; Park YJ; Kim D; Kwon YH; Shin JK; Park O
    Vaccine; 2016 Mar; 34(13):1623-1629. PubMed ID: 26850759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Commentary: Pneumococcal immunization may not be cost-effective in the elderly in developed countries.
    Waugh N
    Int J Epidemiol; 2005 Jun; 34(3):575-6. PubMed ID: 15764693
    [No Abstract]   [Full Text] [Related]  

  • 14. Chapter 26: Innovative financing mechanisms to accelerate the introduction of HPV vaccines in developing countries.
    Batson A; Meheus F; Brooke S
    Vaccine; 2006 Aug; 24 Suppl 3():S3/219-25. PubMed ID: 16950010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pneumococcal conjugate vaccine: economic issues of the introduction of a new childhood vaccine.
    Ray GT
    Expert Rev Vaccines; 2002 Jun; 1(1):65-74. PubMed ID: 12908513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing countries roll out pneumococcal vaccine thanks to novel funding scheme.
    Kmietowicz Z
    BMJ; 2010 Dec; 341():c7230. PubMed ID: 21159770
    [No Abstract]   [Full Text] [Related]  

  • 17. New conjugate vaccines for the prevention of pneumococcal disease in developing countries.
    Ginsburg AS; Alderson MR
    Drugs Today (Barc); 2011 Mar; 47(3):207-14. PubMed ID: 21494698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conjugate pneumococcal vaccines: an overview.
    Mulholland EK
    Med J Aust; 2000 Oct; 173(S2):S48-50. PubMed ID: 11062808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland.
    Ess SM; Schaad UB; Gervaix A; Pinösch S; Szucs TD
    Vaccine; 2003 Jul; 21(23):3273-81. PubMed ID: 12804858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.